Correction: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer

Abstract

[This corrects the article DOI: 10.18632/oncotarget.28068.].

Supplementary Figure 1. Histopathological analysis of lung sections in control animal and upon monotherapy or drug combination treatments.

Representative images of paraffin-embedded sections of lungs stained with H&E from the different experimental groups: (A) Healthy control, or administered intraperitoneally (i.p.) with: (B) vehicle, (C) 4bt (80 mg/Kg), (D) 4bc (80 mg/Kg), (E) paclitaxel (20 mg/Kg), (F) Doxorubicin (10 mg/Kg) + Cyclophosphamide (100 mg/Kg) followed by paclitaxel (10 mg/Kg) (AC-T) and (G) Doxorubicin (10 mg/Kg) + Cyclophosphamide (100 mg/Kg) followed by KIF11 inhibitor 4bt (AC-4bt). Metastatic foci or morphological alterations were not observed in any experimental group compared to control of healthy animals. Bars: 200 μm.